NCT06189170 Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients
| NCT ID | NCT06189170 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Kariya Pharmaceuticals |
| Condition | Safety Issues |
| Study Type | INTERVENTIONAL |
| Enrollment | 88 participants |
| Start Date | 2024-08-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 88 participants in total. It began in 2024-08-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will explore the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of KP405 as a potential new treatment for Parkinson's disease.
Eligibility Criteria
Inclusion Criteria: * Healthy as determined by a responsible physician, based on medical evaluation including medical history, physical examination, concomitant medication, vital signs, 12-lead ECG, cardiac Holter monitoring and clinical laboratory evaluations. * Clinical diagnosis of Parkinson's disease meeting United Kingdom Brain Bank criteria. Exclusion Criteria: * Clinically relevant history of abnormal physical or mental health interfering with the study as determined by medical history and physical examinations obtained during Screening as judged by the Investigator (including \[but not limited to\], neurological, psychiatric, endocrine, cardiovascular, respiratory, gastrointestinal, hepatic, or renal disorder), excluding Parkinson's disease. * Clinically significant, as judged by the Investigator, neurologic disorder (other than Parkinson's disease) including history of stroke or transient ischaemic attack within 12 months of Screening, cognitive impairment, seizure within 5 years of Screening or head trauma with loss of consciousness within 6 months of Screening.
Contact & Investigator
Ezanul A Wahab, MD
PRINCIPAL INVESTIGATOR
MAC
Frequently Asked Questions
Who can join the NCT06189170 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Safety Issues. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06189170 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06189170 currently recruiting?
Yes, NCT06189170 is actively recruiting participants. Contact the research team at Ian.laquian@kariyapharma.com for enrollment information.
Where is the NCT06189170 trial being conducted?
This trial is being conducted at Manchester, United Kingdom.
Who is sponsoring the NCT06189170 clinical trial?
NCT06189170 is sponsored by Kariya Pharmaceuticals. The principal investigator is Ezanul A Wahab, MD at MAC. The trial plans to enroll 88 participants.